In Vivo Efficacy and Pharmacokinetics of AC98-6446, a Novel Cyclic Glycopeptide, in Experimental Infection Models

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1708-1712

  Weiss, William J ^a,b   Murphy, Timothy ^a   Lenoy, Eileen ^a   Young, Mairead ^a  

^a WYETH RESEARCH   (United States)

^b Cumbre Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 98 6446; CYCLIC GLYCOPEPTIDE; CYCLOPEPTIDE; MANNOPROTEIN; NATURAL PRODUCT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENDOCARDITIS; EXPERIMENTAL INFECTION; FEMALE; HOSPITAL INFECTION; LETHALITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STREPTOMYCES HYGROSCOPICUS;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; COLONY COUNT, MICROBIAL; DOGS; ENDOCARDITIS, BACTERIAL; FEMALE; GLYCOPEPTIDES; HALF-LIFE; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; MICE; RATS; RATS, WISTAR; SPECIES SPECIFICITY; THIGH; VANCOMYCIN;

EID: 2142765933     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1708-1712.2004     Document Type: Article

References (30)

1. Calderon, E., J. Arredo-Garcia, F. Aguilar, and P. Garcia-Roca. 2003. In vitro antimicrobial susceptibility in clinical isolates of Enterococcus species. Salud Publica de Mexico 45:96-101.
2. Chavers, L., S. Moser, W. Benjamin, S. Banks, J. Steinhauer, A. Smith, C. Johnson, E. Funkhouser, L. Chavers, A. Stamm, and K. Waites. 2003. Vancomycin-resistant Enterococci: 15 years and counting. J. Hosp. Infect. 53:159-171.
3. Denis, O., C. Nonhoff, B. Byl, C. Knoop, S. Bobin, and M. Struelens. 2002. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital. J. Antimicrob. Chemother. 50:383-391.
4. Eliopoulos, G. 1992. Enterococcal endocarditis, p. 209-223. In D. Kaye (ed.), Infective endocarditis, 2nd ed. Raven Press Ltd., New York, N.Y.
5. Finney, D. 1971. Probit analysis, 3rd ed. Cambridge University Press, London, United Kingdom.
6. Fluit, A., C. Wielders, J. Verhoef, and F. Schmitz. 2001. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J. Clin. Microbiol. 39:3727-3732.
7. Grohskopf, L., R. Sinkowitz, D. Garrett, A. Sohn, G. Levine, J. Siegel, B. Stover, and W. Jarvis. 2002. A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States. J. Pediatr. 140:432-438.
8. He, H., T. Williamson, B. Shen, E. Graziani, H. Yang, S. Sakya, P. Petersen, and G. Carter. 2002. Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J. Am. Chem. Soc. 124:9729-9736.
9. Joels, C., B. Matthews, L. Sigmon, R. Hansan, C. Lohr, K. Kercher, J. Norton, R. Sing, and B. Heniford. 2003. Clinical characteristics and outcomes of surgical patients with vancomycin-resistant enterococcal infections. Am. Surg. 69:514-519.
10. Johnson, A., M. Warner, G. Hallas, and D. Livermore. 2000. Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999. J. Antimicrob. Chemother. 46:125-128.
11. Lai, K., S. Fontecchio, A. Kelly, S. Baker, and Z. Melvin. 2003. The changing epidemiology of vancomycin-resistant enterococci. Infect. Control Hosp. Epidemiol. 24:264-268.
12. Lepelletier, D., and H. Richet. 2001. Surveillance and control of methicillin-resistant Staphylococcus aureus infections in French hospitals. Infect. Control Hosp. Epidemiol. 22:677-682.
13. Linares, J. 2001. The VISA/GISA problem: therapeutic implications. Clin. Microbiol. Infect. 7(Suppl. 4):8-15.
14. Livermore, D. 2000. Antibiotic resistance in staphylococci. Int. J. Antimicrob. Agents 16(Suppl. 1):S3-S10.
15. Mendelson, G., Y. Yearmack, E. Granot, J. Ben-Israel, R. Colodner, and R. Raz. 2003. Staphylococcus aureus carrier state among elderly residents of a long term care facility. J. Med. Direct. Assoc. 4:125-127.
16. Murphy, T, J. Deitz, P. Petersen, S. Mikels, and W. Weiss. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.
17. Mutnick, A., D. Biedenbach, and R. Jones. 2003. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Program. Diagn. Micrbiol. Infect. Dis. 46:63-68.
18. Nilius, A. 2003. Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class. Curr. Opin. Investig. Drugs 4:149-155.
19. Pacio, G., P. Visintainer, G. Maguire, G. Wormser, J. Raffalli, and M. Montecalvo. 2003. Natural history of colonization with vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and resistant gram-positve bacilli among long term care facility residents. Infect. Control Hosp. Epidemiol. 24:246-250.
20. Pechere, J. 1999. Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin. J. Antimicrob. Chemother. 44(Suppl. A):11-18.
21. Rahim, S., S. Pillai, H. Gold, L. Venkataraman, K. Inglima, and R. Press. 2003. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin. Infect. Dis. 36:146-148.
22. Rennie, R., R. Jones, and A. Mutnick. 2003. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 45:287-293.
23. Rybak, M., and R. Akins. 2001. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs 61:1-7.
24. Sieradzki, K., T. Leski, J. Dick, L. Borio, and A. Tomasz. 2003. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J. Clin. Microbiol. 41:1687-1693.
25. Singh, M., P. Petersen, W. Weiss, J. Janso, S. Luckman, E. Lenoy, P. Bradford, R. Testa, and M. Greenstein. 2003. Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygoscopicus LL-AC98: antibacterial and mechanistic activities. Antimicrob. Agents Chemother. 47:62-69.
26. Sobel, J. 1992. Nosocomial infective endocarditis, p. 316. In D. Kaye (ed.), Infective endocarditis, 2nd ed. Raven Press Ltd., New York, N.Y.
27. Strahilevitz, J., and E. Rubenstein. 2002. Novel agents for resistant gram-positive infections - a review. Inter. J. Infect. Dis. 6(Suppl. 1):S38-S46.
28. Sum, P., D. How, N. Torres, P. Petersen, E. Lenoy, W. Weiss, and T. Mansour. 2003. Novel ether derivatives of mannopeptimycin glycopeptide antibiotic. Bioorg. Med. Chem. Lett. 13:1151-1155.
29. Tenover, F. 1999. Implications of vancomycin-resistant Staphylococcus aureus. J. Hosp. Infect. 43(Suppl.):S3-S7.
30. Zhang, Y., S. Geng, F. Lai, and N. Wang. 2002. Survey of drug resistance to ciprofloxacin in common pathogenic bacteria. Di Yi Jun Daxue Xuebao 22:373-379.